Autolus Therapeutics to Participate in Upcoming Investor Conferences
Get Alerts AUTL Hot Sheet
Join SI Premium – FREE
LONDON and GAITHERSBURG, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in two upcoming investor conferences.
TD Cowen 46th Annual Health Care Conference
Date and time: March 3, 2028; 11:10am EST / 4:10pm GMT
Location: Boston, MA
Presenter: Chief Executive Officer Dr. Christian Itin
A webcast of the presentation will be available on the “Events” page in the “Investor Relations & Media” section of the Company’s website at https://www.autolus.com/investor-relations-media/events/. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.
Jefferies Biotech on the Beach Summit
Management to host investor meetings
Date: March 10, 2026
Location: Miami, FL
About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.
Contact:
Amanda Cray
+1 617-967-0207
[email protected]
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Appointment of Non-Executive Directors
- Last Chance to Join the Apeing Whitelist Before This Upcoming Crypto Coin Rivals Monero and Ethereum
- BNP PARIBAS GROUP: SUDAN LITIGATION STATEMENT FROM BNP PARIBAS
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Jefferies & Co, Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share